T. Rowe Price Associates’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

T. Rowe Price Associates’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-48,900	Closed	-$74K	–	3010
2023 Q1	$74K	Hold	48,900	–	–	﹤0.01%	2738
2022 Q4	$49K	Buy	48,900 +14,700	+43%	+$19.8K	﹤0.01%	2814
2022 Q3	$62K	Hold	34,200	–	–	﹤0.01%	2805
2022 Q2	$99K	Sell	34,200 -2,581	-7%	-$6.37K	﹤0.01%	2758
2022 Q1	$102K	Buy	36,781 +500	+1%	+$1.57K	﹤0.01%	2843
2021 Q4	$169K	Buy	+36,281	New	+$227K	﹤0.01%	2795

T. Rowe Price Associates's TCRR Position: Q2 2023 in Review

T. Rowe Price Associates sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 48,900 shares — an estimated $74K sold.

T. Rowe Price Associates first reported a position in TCRR in Q4 2021 and held it in 6 quarters. The position peaked at $169K in Q4 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

T. Rowe Price Associates reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Associates sold 48,900 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $74K.
T. Rowe Price Associates first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 6 quarters.
T. Rowe Price Associates's TCR2 Therapeutics Inc. Common Stock position peaked at $169K in Q4 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.